US10626107, Example Palbociclib US9957276, PD0332991 US12312355, Compound Palbociclib US10696682, Compound PD0332991 Palbociclib US10189849, PD0332991 Pyrido-[2,3-d]-pyrimidin-7-one 43 8-cyclopentyl-6-acetyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H,8H-pyrido[2,3-d]pyrimidin-7-one US10927120, PD0332991 BDBM6309 US20250066372, Example Palbociclib 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one Hydrochloride US10464927, Compound Palbociclib US9464092, PD0332991 PD 0332991 Ibrance
- Shan, H; Ma, X; Yan, G; Luo, M; Zhong, X; Lan, S; Yang, J; Liu, Y; Pu, C; Tong, Y; Li, R Discovery of a novel covalent CDK4/6 inhibitor based on palbociclib scaffold. Eur J Med Chem 219: (2021)
- Wang, P; Huang, J; Wang, K; Gu, Y New palbociclib analogues modified at the terminal piperazine ring and their anticancer activities. Eur J Med Chem 122: 546-556 (2016)
- Poratti, M; Marzaro, G Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib. Eur J Med Chem 172: 143-153 (2019)
- Fang, L; Chu, M; Yan, C; Liu, Y; Zhao, Z Palbociclib and Michael-acceptor hybrid compounds as CDK4/6 covalent inhibitors: Improved potency, broad anticancer spectrum and overcoming drug resistance. Bioorg Med Chem 84: (2023)
- Li, Y; Zhao, J; Gutgesell, LM; Shen, Z; Ratia, K; Dye, K; Dubrovskyi, O; Zhao, H; Huang, F; Tonetti, DA; Thatcher, GRJ; Xiong, R Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib. J Med Chem 63: 7186-7210 (2020)